NEW YORK, NY / ACCESSWIRE / May 30, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ: PRTA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Prothena and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On April 23, 2018, Prothena announced that it “is discontinuing development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis.” The Company advised investors that “[b]ased on the results from the Phase 2b PRONTO study, which did not meet its primary or secondary endpoints, the Company asked the independent data monitoring committee (DMC) of the Phase 3 VITAL study to review a futility analysis of the ongoing VITAL study. The DMC recommended discontinuation of the VITAL study for futility.” On this news, Prothena’s share price fell $25.34, or 68.78%, to close at $11.50 on April 23, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

ReleaseID: 501283

PHOENIX, AZ / ACCESSWIRE / May 30, 2018 / Crexendo, Inc. (OTCQX: CXDO), a next-generation CLEC and an award-winning leader and provider of unified communications cloud telecom services, broadband internet services, and other cloud business services that are designed to provide enterprise-class cloud services to any size business at affordable monthly rates, today announced that Doug Gaylor, President and COO, and Ron Vincent, CFO, are scheduled to attend and present at the 8th annual LD Micro Invitational being held June 4-6 in Los Angeles, CA. Mr. Gaylor will be presenting Monday, June 4th at 2:00 in the Track 3 Presentation Room. Mr. Gaylor and Mr. Vincent will also host one-on-one investor meetings throughout the day as well as Tuesday, June 5th and the morning of Wednesday, June 5.

A copy of the presentation is available at http://www.crexendo.com/investor.

“The event is slated to be our largest Invitational to date,” stated Chris Lahiji, President of LD Micro. “When the fires caused the cancellation of our Main Event back in December, we vowed to come back even stronger. This event showcases our firm’s ability to attract the most unique and exciting names in micro-cap.”

The conference will be held at the Luxe Sunset Bel Air Hotel, will feature 230 companies in the small-cap/ micro-cap space, and will be attended by over 1,000 individuals.

Safe Harbor Statement

This press release contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “will” and other similar statements of expectation identify forward-looking statements. For a more detailed discussion of risk factors that may affect Crexendo’s operations and results, please refer to the company’s Form 10-K for the year ended December 31, 2017, and quarterly Form 10-Qs as filed with the SEC. These forward-looking statements speak only as of the date on which such statements are made, and the company undertakes no obligation to update such forward-looking statements, except as required by law.

CONTACT:

Crexendo, Inc.
Steven G. Mihaylo, CEO
Smihaylo@crexendo.com
602-345-7777

SOURCE: Crexendo, Inc.

ReleaseID: 501273

NEW YORK, NY / ACCESSWIRE / May 30, 2018 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Aceto Corporation (“Aceto”) (NASDAQ: ACET) securities between August 25, 2017 and April 18, 2018.

Click here to learn about the case: http://www.wongesq.com/pslra-c/aceto-corporation?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company failed to implement and enforce proper internal control to identify the misapplication of cash; (ii) the Company would incur large non-cash intangible asset impairment charges; (iii) the Company lacked effective internal control over financial reporting; (iv) the Company’s financial results for the fiscal year 2017 could not be relied upon; (v) the Company’s fiscal 2018 financial guidance was overstated; and (vi) as a result of the foregoing, Aceto’s public statements were materially false and misleading at all relevant times. On April 18, 2018, Aceto issued a press release disclosing non-reliance on the previously issued 2018 fiscal year earnings guidance and the recording of non-cash intangible asset impairment charges, including goodwill, in the range of $230-$260 million.

If you suffered a loss in Aceto you have until June 25, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/aceto-corporation?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
vw@wongesq.com

SOURCE: Vincent Wong, Esq.

ReleaseID: 501271

LAS VEGAS, NV / ACCESSWIRE / May 30, 2018 / Capital Art, Inc. (OTC PINK: CAPA), a marketer and distributor of vintage iconic pop culture images for the art, editorial and commercial markets, has been invited to present at the 8th Annual LD Micro Invitational Conference being held on June 4-6, 2018 at the Luxe Sunset Bel Air Hotel in Bel Air, California.

Capital Art’s CEO Stuart Scheinman is scheduled to present on Wednesday, June 6, at 10:00 a.m. Pacific time. He will be joined by the company’s Chairman Sam Battistone and CFO Scott Black for one-on-one meetings held throughout the day. They will discuss Capital Art’s recently reported first profitable quarter and the company’s library of vintage Pop Culture imagery, one of the largest and most diverse collections in the world.

The presentation will be also webcast live and available for replay here and via the investor relations section of the company’s website at www.capitalarts.com.

The LD Micro Invitational Conference is one of the nation’s largest independent conferences for small/micro-cap companies, with more than 230 names presenting to 1,000+ attendees. The conference will also feature variety of speakers and panelists discussing topics of interest to investors and issuers, as well as evening social events.

To schedule a one-on-one meeting with Capital Art, you may submit your request online via the link provided upon registration. To register for the conference, contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events. For any questions about the company, contact Ron Both of CMA at (949) 432-7557 or submit your request here.

View Capital Art’s LD Micro profile here: https://www.ldmicro.com/profile/CAPA.

Profiles powered by LD Micro – News Compliments of ACCESSWIRE.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential conferences annually. In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. For more information about LD Micro, go to www.ldmicro.com/events.

About Capital Art

Founded in 2004, Capital Art, Inc. acquires and manages Iconic Pop Culture photographic image libraries. It has one of the largest and most diverse collections of vintage Pop Culture imagery in the world, with more than 10 million iconic images that feature the most beloved Hollywood idols, music stars and most iconic figures of the 20th century. The company markets and distributes images for the art, editorial and commercial markets. Capital Art also sells limited editions of its photographs through the company owned gallery and through third party galleries, art consultants and interior decorators. For further information, visit www.capitalart.com.

Important Cautions Regarding Forward Looking Statements

Cautionary statement for purposes of the ”Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995: Information in this news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of the Company and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties and assumptions include the execution and performance of contracts by the Company and its customers, suppliers and partners. The Company disclaims any obligation to update or revise statements contained in this news release based on new information or otherwise.

Company Contact

Stuart Scheinman
President & Co-CEO
Capital Art, Inc.
Tel (702) 722-6113
info@capitalart.com

Investor Relations:

Ronald Both
CMA Investor Relations
Tel (949) 432-7566
CAPA@cma.team

SOURCE: Capital Art, Inc.

ReleaseID: 501270

RADNOR, PA / ACCESSWIRE / May 30, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP announces that an investor class action lawsuit has been filed against Esperion Therapeutics, Inc. (NASDAQ: ESPR) (“Esperion”) on behalf of purchasers of Esperion securities between February 22, 2017 and May 1, 2018, inclusive (the “Class Period”).

Deadline Reminder: Investors who purchased Esperion securities during the Class Period may, no later than July 6, 2018, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action please visit https://www.ktmc.com/new-cases/esperion-therapeutics-inc-2018#join

According to the complaint, Esperion is a biopharmaceutical company that is primarily focused on the research and development of oral and small molecule therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol and other cardio metabolic risk factors. Bempedoic acid and its lead product candidate, the bempedoic acid/ezetimibe combination pill, are targeted therapies focused on reducing elevated LDL-C levels in patients with hypercholesterolemia. The company owns the exclusive worldwide rights to bempedoic acid.

The Class Period commences on February 22, 2017, when Esperion filed a press release with the SEC entitled “Esperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial Results,” wherein it provided bempedoic acid development program updates.

According to the complaint, on May 2, 2018, Esperion announced results from its second pivotal Phase 3 study for its cholesterol-lowering medication. Esperion reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group. Following this news, Esperion’s share price fell $24.75, or 35.10%, to close at $45.75 on May 2, 2018.

The complaint alleges that, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) Esperion’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and (ii) as a result of the foregoing, Esperion’s public statements were materially false and misleading at all relevant times.

Esperion investors may, no later than July 6, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 501263

NEW YORK, NY / ACCESSWIRE / May 30, 2018 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of LendingClub Corporation (“LendingClub”) (NYSE: LC) between February 28, 2015 and April 25, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information go to:

http://www.zlk.com/pslra-d/lendingclub-lc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) LendingClub falsely promised consumers they would receive a loan with “no hidden fees”; (2) LendingClub’s privacy policy did not comply with the Gramm-Leach-Bliley Act; (3) consequently, the foregoing conduct would subject LendingClub’s business practices to heightened regulatory scrutiny by the Federal Trade Commission (“FTC”); and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

On April 25, 2018, the FTC issued a press release announcing allegations that LendingClub violated the FTC Act and the Gramm-Leach-Bliley Act by falsely promising consumers they would receive a loan without hidden fees and failing to provide customers with a clear and conspicuous privacy notice.

If you suffered a loss in LendingClub you have until July 2, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 501256

NEW YORK, NY / ACCESSWIRE / May 30, 2018 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Edge Therapeutics, Inc. (“Edge Therapeutics”) (NASDAQ: EDGE) between December 29, 2017 and March 27, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:

http://www.zlk.com/pslra-d/edge-therapeutics-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Edge Therapeutics lead product candidate EG-1962 would likely fail a futility analysis in connection with the NEWTON 2 study; and (2) as a result of the foregoing, the Company’s financial statements and Defendants’ statements about Edge’s business, operations, and prospects, were materially false and misleading at all relevant times.

If you suffered a loss in Edge Therapeutics you have until June 22, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 501255